Visao Geral da Pesquisa Ipamorelin (NNC 26-0161) is a synthetic pentapeptide hormonio do crescimento secretagogue with a sequencia Aib-His-D-2-Nal-D-Phe-Lys-NH₂, developed by Novo Nordisk no(a) mid-1990s by systematic modification of GHRP-1. It acts como um(a) highly selective agonist do(a) GHS-R1a receptor (ghrelin receptor), stimulating potent, pulsatile hormonio do crescimento release sem affecting ACTH, cortisol, FSH, LH, TSH, or prolactin — even at 200× o efeitoive dose.[1][2] Ipamorelin re

How does Ipamorelin work? What is its mechanism of action?

Mecanismo de Acao Ipamorelin ativa the GHS-R1a (ghrelin receptor) on pituitary somatotroph cells with an in vitro EC₅₀ of 1.3 ± 0.4 nmol/L e em vivo ED₅₀ of 2.3 nmol/kg (swine). Binding desencadeia phospholipase C (PLC) ativacao via Gα₁₁/q → IP3 → intracellular Ca²⁺ release → GH vesicle exocytosis — a pathway distinto(a) de GHRH's cAMP signaling.[1][2] Receptor & Signaling Profile TargetActionDownstream Effect GHS-R1a (Ghrelin Receptor)Selective agonistPLC → IP3 → Ca²⁺ → GH vesicle exocytosis cA

What are the research applications of Ipamorelin?

Aplicacoes de Pesquisa Ipamorelin research spans 8+ indication categories across GH physiology, GI motility, musculoskeletal biology, and pain: Selective GH Secretion — Pulsatile GH release sem ACTH/cortisol effects; potency comparable to GHRP-6 but with GHRH-like selectivity.[1] Postoperative Ileus (POI) — Accelerates gastric emptying via GHS-R1a on cholinergic neurons; reduz stomach retention to <25% (vs 78% vehicle). The Phase II trial did not meet its primary endpoint.[4][6] Bone Growth &

What does the research summary say about Ipamorelin?

Resumo da Pesquisa Pre-clinica Key Preclinical Studies EstudoModeloPrincipais AchadosRef Raun et al. (1998)Rats/SwineED₅₀ = 80 nmol/kg (rats), 2.3 nmol/kg (swine); NO ACTH/cortisol even at >200× ED₅₀; primeiro(a) selective GHS[1] Johansen et al. (1999)Adult female rats — 15-day studyLongitudinal bone growth 42→52 µm/day (p<0.0001); dose-dependente[3] Andersen et al. (2001)Rats — GC-induziu catabolism — 100 µg/kg TID × 3moPeriosteal bone formation rate aumentou 4-fold; aumentou maximum tetanic

How should Ipamorelin be stored?

Liofilizado: -18°C to -20°C (estável vários anos); proteja da luz.

Ipamorelin Research Applications — Scientific Studies & Evidence

Q: What does the research summary say about Ipamorelin?

Resumo da Pesquisa Pre-clinica Key Preclinical Studies EstudoModeloPrincipais AchadosRef Raun et al. (1998)Rats/SwineED₅₀ = 80 nmol/kg (rats), 2.3 nmol/kg (swine); NO ACTH/cortisol even at >200× ED₅₀; primeiro(a) selective GHS[1] Johansen et al. (1999)Adult female rats — 15-day studyLongitudinal bone growth 42→52 µm/day (p<0.0001); dose-dependente[3] Andersen et al. (2001)Rats — GC-induziu catabolism — 100 µg/kg TID × 3moPeriosteal bone formation rate aumentou 4-fold; aumentou maximum tetanic

Q: How should Ipamorelin be stored?

Liofilizado: -18°C to -20°C (estável vários anos); proteja da luz.

Aplicacoes de Pesquisa

Ipamorelin research spans 8+ indication categories across GH physiology, GI motility, musculoskeletal biology, and pain:

Selective GH Secretion — Pulsatile GH release sem ACTH/cortisol effects; potency comparable to GHRP-6 but with GHRH-like selectivity.[1]
Postoperative Ileus (POI) — Accelerates gastric emptying via GHS-R1a on cholinergic neurons; reduz stomach retention to <25% (vs 78% vehicle). The Phase II trial did not meet its primary endpoint.[4][6]
Bone Growth & Metabolism — Dose-dependent longitudinal bone growth (42→52 µm/day, p<0.0001); aumentou tibial/vertebral BMC in adult rats.[3][8]
Glucocorticoid-Induced Catabolism — Counteracts GC-induziu diminui: periosteal bone formation rate aumentou 4-fold; aumentou maximum tetanic muscle tension.[12]
Body Composition & Adiposity — GH-independent adipogenic effects; aumenta food intake and serum leptin in ambos(as) GH-deficient and GH-intact mice.[9]
Insulin Secretion — Stimulates insulin release via calcium channels and adrenergic receptor pathways in normal and diabetic pancreatic tissue.[10]
Pain Modulation / Nociception — Attenuates visceral and somatic nociception via periferico(a) ghrelin receptors; dose-dependente reduction in visceromotor response.[17]
Cancer Cachexia / Emesis — Ferret cisplatin model: body-weight and emesis endpoints reported.[14]

Aplicacoes de Pesquisa

Ipamorelin research spans 8+ indication categories across GH physiology, GI motility, musculoskeletal biology, and pain:

Selective GH Secretion — Pulsatile GH release sem ACTH/cortisol effects; potency comparable to GHRP-6 but with GHRH-like selectivity.[1]
Postoperative Ileus (POI) — Accelerates gastric emptying via GHS-R1a on cholinergic neurons; reduz stomach retention to <25% (vs 78% vehicle). The Phase II trial did not meet its primary endpoint.[4][6]
Bone Growth & Metabolism — Dose-dependent longitudinal bone growth (42→52 µm/day, p<0.0001); aumentou tibial/vertebral BMC in adult rats.[3][8]
Glucocorticoid-Induced Catabolism — Counteracts GC-induziu diminui: periosteal bone formation rate aumentou 4-fold; aumentou maximum tetanic muscle tension.[12]
Body Composition & Adiposity — GH-independent adipogenic effects; aumenta food intake and serum leptin in ambos(as) GH-deficient and GH-intact mice.[9]
Insulin Secretion — Stimulates insulin release via calcium channels and adrenergic receptor pathways in normal and diabetic pancreatic tissue.[10]
Pain Modulation / Nociception — Attenuates visceral and somatic nociception via periferico(a) ghrelin receptors; dose-dependente reduction in visceromotor response.[17]
Cancer Cachexia / Emesis — Ferret cisplatin model: body-weight and emesis endpoints reported.[14]

Ipamorelin: Research Applications

Aplicacoes de Pesquisa

Referencias

Perguntas de Pesquisa Relacionadas

Related research

Ipamorelin: Research Applications

Aplicacoes de Pesquisa

Referencias

Perguntas de Pesquisa Relacionadas

Related research